Literature DB >> 17763456

Species differences in inhibition potential of nonsteroidal anti-inflammatory drugs against estradiol 3beta-glucuronidation between rats, dogs, and humans.

Yuji Mano1, Takashi Usui, Hidetaka Kamimura.   

Abstract

Differences in the inhibitory potentials against UDP-glucuronosyltransferase (UGT) between species have been reported only rarely, even though the information would be useful for the precise characterization of drug candidates. In this study, the inhibition potentials of nonsteroidal anti-inflammatory drugs (NSAIDs) against UGT-catalyzed estradiol 3beta-glucuronidation (E3G) in the liver microsomes of rats, dogs, and humans were compared. Rat liver microsomes (RLMs) and human liver microsomes (HLMs) exhibited homotropic activation kinetics with S(50) values of 22 and 12 microM, respectively. However, dog liver microsomes (DLMs), exhibited Michaelis-Menten kinetics with no activation. Among the NSAIDs investigated (diclofenac, diflunisal, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, mefenamic acid, niflumic acid, and sulindac), only niflumic acid and mefenamic acid inhibited E3G potently in all three species. The IC(50) values of NSAIDs against E3G in RLMs and HLMs were within a threefold difference of each other, while those in DLMs was more than three times higher than the other two. In conclusion, RLMs showed an inhibitory pattern similar to that of HLMs, whereas DLMs presented a distinct pattern. These results indicate that a rat animal model would be useful for evaluating the inhibitory potentials of drugs against estradiol glucuronidation, but a dog model would not.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17763456     DOI: 10.1002/jps.21185

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Demethylzeylasteral exhibits dose-dependent inhibitory behaviour towards estradiol glucuronidation.

Authors:  Su-Lin Liu; Shu-Yao Zhang; Miao-Jun Wang; Hong Jiang; Yu-Xian Yang; Lei Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-27       Impact factor: 2.441

2.  Case Study 6: Deconvoluting Hyperbilirubinemia-Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development.

Authors:  Ian Templeton; Gary Eichenbaum; Rucha Sane; Jin Zhou
Journal:  Methods Mol Biol       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.